Published online before print February 7, 2008

This Article Full Text Full Text (PDF) All Versions of this Article: jmoldx.2008.070115v1 jmoldx.2008.070115v2 10/2/111    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Feldmann, G. Articles by Maitra, A. PubMed PubMed Citation Articles by Feldmann, G. Articles by Maitra, A.

Journal of Molecular Diagnostics 2008, Vol. 10, No. 2
Copyright © 2008 American Society for Investigative Pathology & Association for Molecular Pathology
DOI: 10.2353/jmoldx.2008.070115

Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts

From The Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Pancreatic ductal adenocarcinoma (ie, pancreatic cancer) is among the most devastating of human malignancies. It is commonly diagnosed at advanced, already metastatic, and, hence, incurable stages. Despite extensive research efforts in recent decades, pancreatic cancer remains resistant to almost all clinically available therapy regimens. Recent advances in our understanding of the underlying pathophysiology and molecular biology have opened up avenues for the development of novel diagnostic and therapeutic strategies, some of which have shown highly promising preclinical results and are currently being translated into clinical application. Here in we present a review of recent literature on the molecular genetics of pancreatic cancer and emphasize clinical implications for the development of novel diagnostic and therapeutic approaches.